This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABT-089

AbbVie Inc.

Drug Names(s): ABT-089, pozanicline

Description: ABT-089 is a selective neuronal nicotinic acetylcholine receptor (nAChR) modulator (partial agonist) with cognitive enhancing properties. Amongst NNR subtypes, ABT-089 shows selectivity for the cytisine binding site on the alpha4beta2 receptor subtype as compared to the alpha-bungarotoxin (alpha-BgT) binding sites on the alpha7 and alpha1beta1deltagamma receptor subtypes. Studies have shown a reduced number of alpha4beta2 nAChRs in persons with dementia, suggesting the involvement of alpha4beta2 in cognition.


ABT-089 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug